A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer.

In a study scheduled for presentation at Digestive Disease Week later this month, the Rutgers team suggests oral bacteria ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

A study, published in BME Frontiers, introduces a novel approach to cancer biomarker detection using ... bladder cancer, and oral squamous cell carcinoma (OSCC). However, traditional methods ...

‘MRD positivity after treatment often signals cancer recurrence. It’s emerging as a powerful tool to guide therapy, adjust treatments mid-course, and monitor for relapse. #biomarker #cancerinn ...